Carvedilol
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
- Carvedilol
- Pharmacist Assessment Report
- Carvedilol: non-selective β-blocker with α1-blocking activity → malignant hypertensive renal disease
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Carvedilol: non-selective β-blocker with α1-blocking activity → malignant hypertensive renal disease
One-Sentence Summary
Carvedilol is a non-selective β-blocker that also blocks α1-adrenergic receptors. The TxGNN model predicts it may be relevant to malignant hypertensive renal disease. The data compiled for this report contain no clinical trials and no publications on this disease, so the prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | malignant hypertensive renal disease |
| TxGNN Prediction Score | 0.9955 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data are not available in the data compiled for this report. Carvedilol is known as a non-selective β-blocker with α1-adrenergic blocking and antioxidant activity. The rationale for this prediction is extrapolated from that blood-pressure-lowering pharmacology and from reported renal and vascular protective effects.
The link is indirect. Malignant hypertensive renal disease is kidney damage driven by severe, uncontrolled blood pressure, so a drug that lowers blood pressure could plausibly help. No study retrieved for this report examined carvedilol in this condition. The high TxGNN score is probably inflated by the model’s similarity to hypertension-related uses, so it should not be read as clinical evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 13387N | Dilatrend 25 | Tablet 25 mg | Not recorded in the local data |
The single registered product is a valid, single-ingredient oral tablet.
Safety Considerations
- Drug Interactions: The interaction screen was completed and returned 100 interacting drugs, of which 20 are summarised here.
- Major: epinephrine.
- Moderate: hydrocortisone, dexamethasone, betamethasone, triamcinolone, budesonide, hyoscyamine, atropine, bupropion, morphine, lorcaserin, canagliflozin, acetohexamide, and calcium salts (phosphate, acetate, carbonate, citrate).
- Minor: acetylsalicylic acid, aluminium hydroxide, attapulgite.
Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: There are no clinical trials or publications for malignant hypertensive renal disease, so the evidence level is L5. The prediction score alone is not enough to support a repurposing decision.
To proceed, the following is needed:
- Mechanism of action data and a clear mechanistic argument for this kidney condition
- Preclinical or clinical studies that directly address malignant hypertensive renal disease
- Review of TGA Product Information warnings and contraindications for a severely hypertensive, renally impaired population
- Review of the interaction profile, especially the major interaction with epinephrine
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.